Health Care [ 4/12 ] | Biotechnology [ 18/73 ]
NASDAQ | Common Stock
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.16 Decreased by -6.67% | 0.02 Decreased by -900.00% |
| Aug 13, 25 | -0.06 Increased by +81.82% | -0.14 Increased by +57.14% |
| May 5, 25 | -0.21 Decreased by -160.68% | -0.15 Decreased by -37.53% |
| Feb 25, 25 | -0.10 Increased by +79.74% | -0.16 Increased by +35.68% |
| Nov 5, 24 | -0.15 Increased by +59.46% | -0.18 Increased by +16.67% |
| Aug 12, 24 | -0.33 Increased by +28.26% | -0.18 Decreased by -83.33% |
| May 7, 24 | 0.34 Increased by +143.04% | 0.05 Increased by +580.00% |
| Feb 27, 24 | -0.50 Increased by +34.21% | -0.48 Decreased by -4.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 87.31 M Increased by +69.10% | -31.33 M Decreased by -6.13% | Decreased by -35.89% Increased by +37.24% |
| Jun 30, 25 | 82.39 M Increased by +11.58% | -12.72 M Increased by +79.45% | Decreased by -15.45% Increased by +81.58% |
| Mar 31, 25 | 65.00 M Decreased by -52.81% | -40.45 M Decreased by -166.30% | Decreased by -62.24% Decreased by -240.49% |
| Dec 31, 24 | 69.11 M Increased by +114.30% | -21.32 M Increased by +62.16% | Decreased by -30.85% Increased by +82.34% |
| Sep 30, 24 | 51.63 M Increased by +52.00% | -29.52 M Increased by +28.43% | Decreased by -57.18% Increased by +52.91% |
| Jun 30, 24 | 73.83 M Increased by +186.33% | -61.92 M Decreased by -24.01% | Decreased by -83.87% Increased by +56.69% |
| Mar 31, 24 | 137.74 M Increased by +466.14% | 61.02 M Increased by +198.87% | Increased by +44.30% Increased by +117.46% |
| Dec 31, 23 | 32.25 M Increased by +71.38% | -56.34 M Decreased by -1.54% | Decreased by -174.71% Increased by +40.75% |